biguanides has been researched along with glucagon-like peptide 1 in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Inoue, T; Kira, K; Nagakura, T; Saeki, T; Tanaka, I; Yamazaki, K; Yasuda, N | 2 |
| Purnell, JQ; Weyer, C | 1 |
| Hermansen, K; Mortensen, LS | 1 |
| Rabasseda, X | 2 |
| Chaudhuri, A; Dandona, P | 1 |
| Corathers, SD; Peavie, S; Salehi, M | 1 |
| Abiru, N; Ando, T; Fujishima, K; Haraguchi, A; Imaizumi, M; Kawakami, A; Matsumoto, K; Mori, F; Takamura, N; Yamasaki, H | 1 |
| Davis, SN; Munir, KM | 1 |
| Hartikainen, S; Huovinen, M; Koponen, M; Sunnarborg, K; Tiihonen, M; Tolppanen, AM | 1 |
5 review(s) available for biguanides and glucagon-like peptide 1
| Article | Year |
|---|---|
Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity.
Topics: Amyloid; Benzamides; Biguanides; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Islet Amyloid Polypeptide; Obesity; Peptide Fragments; Protein Precursors; Sulfonylurea Compounds; Thiazolidinediones; Weight Gain | 2003 |
Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.
Topics: Amyloid; Benzamides; Biguanides; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islet Amyloid Polypeptide; Obesity; Sulfonylurea Compounds; Thiazolidinediones; Weight Gain | 2007 |
Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes.
Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiazolidinediones | 2011 |
Complications of diabetes therapy.
Topics: Biguanides; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Islet Amyloid Polypeptide; Sulfonylurea Compounds; Thiazolidinediones | 2013 |
The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus.
Topics: Biguanides; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2015 |
6 other study(ies) available for biguanides and glucagon-like peptide 1
| Article | Year |
|---|---|
Enhanced secretion of glucagon-like peptide 1 by biguanide compounds.
Topics: Animals; Biguanides; Buformin; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; In Vitro Techniques; Male; Metformin; Peptide Fragments; Phenformin; Protease Inhibitors; Protein Precursors; Pyrroles; Rats; Rats, Inbred F344; Valine | 2002 |
The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine weight.
Topics: Animals; Antimetabolites; Biguanides; Dipeptidyl Peptidase 4; Enteroendocrine Cells; Fluorouracil; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Hypoglycemic Agents; Intestine, Small; Male; Metformin; Mice; Mice, Inbred BALB C; Organ Size; Peptides; Protease Inhibitors; Pyrroles; Rats; Rats, Inbred F344; Valine | 2004 |
Insight into antidiabetic therapies: a report from the 43rd annual meeting of the European Association for the Study of Diabetes.
Topics: Amyloid; Biguanides; Diabetes Mellitus; Dietary Supplements; Dipeptidyl-Peptidase IV Inhibitors; Fructose-Bisphosphatase; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Islet Amyloid Polypeptide; Phytotherapy; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones | 2007 |
From insulin to incretins: a report from the 67th scientific sessions of the American Diabetes Association.
Topics: Biguanides; Diabetes Complications; Diabetes Mellitus; Diet; Dietary Supplements; Dipeptidyl-Peptidase IV Inhibitors; Dyslipidemias; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Obesity; Thiazolidinediones | 2007 |
Multiple drug combination of anti-diabetic agents as a predictor for poor clinical response to liraglutide.
Topics: Adult; Aged; Alanine Transaminase; Anthropometry; Biguanides; Body Weight; Comorbidity; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Liraglutide; Male; Middle Aged; Peptides; Prognosis; Retrospective Studies; Sulfonylurea Compounds; Thiazolidines; Treatment Outcome; Venoms | 2014 |
Association between different diabetes medication classes and risk of Parkinson's disease in people with diabetes.
Topics: Biguanides; Case-Control Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Parkinson Disease; Sulfonylurea Compounds; Thiazolidinediones | 2022 |